Last reviewed · How we verify
NCT06808672: MIOSURFACE
Biomarkers of Cancer-Associated Myositis
trial in Dermatomyositis in 50 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2024
Quick facts
| Lead sponsor | Azienda USL Reggio Emilia - IRCCS |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 13 June 2019 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 2 locations across Italy |
Conditions studied
- Dermatomyositis — all drugs for Dermatomyositis →
Sponsor
Azienda USL Reggio Emilia - IRCCS — full company profile →
Who can join
40 and older, any sex, with Dermatomyositis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The project is about dermatomyositis (DM), an autoimmune disease characterized by inflammation in the skeletal muscles and skin. Patients with DM have an increased risk of cancer, with a cancer incidence between 5.5% and 42%. Cancers in these patients are one of the leading causes of death. Some myositis-specific autoantibodies have been discovered and some of them are associated with cancer development. However, DM patients negative for all the known autoantibodies can also develop cancer. The Investigator hypothesized that antibodies against plasma membrane antigens and soluble immune checkpoints can be responsible for the association between cancers and autoimmunity. Therefore, the present study aimed to identify novel antigens and immunological pathways in patients with DM with cancer versus patients with DM without cancer, to identify those patients who need cancer screening. The Investigators focus on soluble immune checkpoint molecules and autoantibodies directed against plasma membrane antigens.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06808672
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dermatomyositis
Currently open trials in the same condition.
- NCT06672822 — Intralesional Injection of STS in Treatment of Calcinosis · Phase 2 · recruiting
- NCT06698796 — A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies · Phase 3 · recruiting
- NCT06732674 — Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases · NA · recruiting
- NCT06686524 — Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refracto · Phase 1 · recruiting
- NCT07037472 — Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treat · NA · recruiting
Other Azienda USL Reggio Emilia - IRCCS trials
Trials by the same sponsor.
- NCT07373626 — Physical Activity Trends in Cancer Survivors Treated at the 'MOvement and REhabilitation' Clinic · recruiting
- NCT07000162 — LAttice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial · Phase 2 · recruiting
- NCT06629896 — Contrast Enhancement Mammography vs MRI for the Surveillance of Women at High Risk of Breast Cancer: Con-trust Randomize · NA · recruiting
- NCT06749600 — Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma · recruiting
- NCT06624280 — Does Orthopedic Surgery Improve Gait Efficiency in Children With Cerebral Palsy? A Retrospective Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06808672 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda USL Reggio Emilia - IRCCS
- Last refreshed: 11 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06808672.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing